Y90 Treatment for Liver Cancer

Introduction

The liver is credited as one of the largest solid internal organs in the human body and is responsible for many processes, ranging from small to big. Hence, it is one of the most vital organs in the body. Cancerous cells might develop in the liver and spread to other body parts. This article deals with managing the condition using Y90 radioembolization.

What Are the Treatment Options for Liver Cancer?

All liver conditions, while they are treatable, are usually managed by surgery, which is the gold standard for liver diseases. However, treatment options are not restricted to surgery. The other minimally invasive options for managing lier conditions in specific areas include transarterial therapy and percutaneous ablation. It may differ from patient to patient, depending upon the severity of the condition. It can include surgery, minimally invasive options, or a combination of many options. The precise treatment plan depends on the cancer's stage, extent of spread, size, etc.

What Is Y-90 Radioembolization for Liver Cancer?

Y-90 radioembolization is a therapy that kills cancerous liver cells with high doses of radiation. It is also called selective internal radiation therapy (SIRT). The radioactive isotope yttrium-90 is inserted into tiny glass beads and the tumor's blood supply. This radioisotope can travel up to a distance of 1 mm in the liver. These tiny beads accumulate in the tumor and are emitted to suppress its growth. The cancerous cells are gradually destroyed, while the healthy liver cells are sustained. The radioactive glass beads, called microspheres, increase blood flow in cancerous cells. On the other hand, normal cells are supplied by the portal vein.

When Is It Recommended for Liver Cancer?

Y-90 radioembolization is recommended for liver cancer in patients where liver transplant and surgery are not feasible. In addition, it can be done in patients who are waiting for a liver transplant, as a precaution to keep the cancer from spreading.

It emerged as an initial treatment option during the early stages of liver cancer, when surgery was not feasible. Radiofrequency ablation is the most preferred mode of treatment during the early stages. It is a minimally invasive procedure in which the heat from the radiation is used to kill the tumor cells. When this is not feasible, TACE (transarterial chemoembolization) is advised. In this procedure, the blood supply to the liver is blocked, and the cells are managed with chemotherapy.

What Are the Benefits of Y90 Radioembolization?

1. It provides precision targeting of the liver tumor cells. The damage to the nearby normal cells is minimal, which is beneficial for a solid organ like the liver, which is a hub of many bodily functions.
2. Being a minimally invasive procedure, the recovery time and the potential complications are less.
3. The treatment option treats the tumor cells directly and provides localized treatment.
4. Studies have shown an improved quality of life for liver cancer patients following Y90 radioembolization. It can be used alone or in combination with other treatment options. The healthcare provider's opinion is required to determine whether it can be used alone or in addition to other methods.

How Successful Is Y90 Radioembolization Treatment in Liver Cancer?

Experts are still studying the success of Y90 radioembolization on liver cancer. Many clinical trials are still ongoing on the same. Some of them include:

• SARAH Trial: The third phase of this trial, conducted in 2017, compared the effectiveness of Y90 radioembolization to targeted therapy using a drug called Sorafenib. The trial was mainly conducted in advanced or intermediate stages of liver cancer, where surgery or radiation ablation were not successful options. It also included cases where TACE was unsuccessful. The average survival rates were almost similar. However, the complications associated with Sorafenib were slightly higher.
• SIRveNIB Trial: In 2018, the third phase of this clinical trial compared Y90 radioembolization to targeted therapy using Sorafenib in locally advanced liver cancer patients. This study also showed similar overall survival rates in both groups.
• SORAMIC Trial: In this trial, the combined effect of Sorafenib and Y90 radioembolization was compared against the sole use of Sorafenib. It did not increase the overall survival rates by adding Y90 radioembolization generally. However, it gave better results in people over 65 years of age, people without cirrhosis, and those who had cirrhosis that was not related to alcohol.

Does Y90 Radioembolization Have Any Adverse Effects?

Generally, the treatment option did not have any major side effects. Fatigue lasting for two to four months was commonly seen in all patients. However, in rare cases, the radioactive glass beads reach other body parts, like the gall bladder, stomach, intestine, or pancreas. Radioactive beads can cause ulceration or inflammation when they reach the organs. Pain, nausea, and low-grade fever are joint after Y90 radioembolization and are called post-embolization syndrome.

These complications are rarely seen. However, if it occurs, they would require additional treatment. These complications can be minimized by finding any blocked blood vessels and managing them appropriately.

How to Care After Y90 Treatment?

Patients are advised to limit contact with many people the week after the procedure. This is mainly due to the possible radiation exposure they might face. The other restrictions in the first week include:

• Sleep alone on a single bed.
• It is only advisable to sit near people for up to two hours.
• All contact with small children and pregnant women should be avoided.

Conclusion

Y90 radioembolization is a minimally invasive therapy for liver cancer in cases where surgery and radiation therapy are not feasible. Tiny radioactive beads with a radioisotope are delivered directly into the cancerous liver cells. The advent of Y90 radioembolization is a ray of hope for liver cancer patients. However, it might not be the best option for all cases. The efficacy of the treatment, in cases where it is feasible, is high and has lesser potential adverse effects. Ongoing research is needed to help this novel option evolve, offering better hopes in managing liver cancer.